Stockscreener 앱 받기
4.19
5.01%
0.20
전일 마감가:
$3.99
열려 있는:
$4.02
하루 거래량:
131.39K
Relative Volume:
0.82
시가총액:
$22.06M
수익:
-
순이익/손실:
$-21.21M
주가수익비율:
-0.1285
EPS:
-32.6
순현금흐름:
$-16.86M
1주 성능:
+3.71%
1개월 성능:
-26.88%
6개월 성능:
-1.87%
1년 성능:
-63.05%
1일 변동 폭
$3.9525
$4.19
1주일 범위
$3.71
$4.21
52주 변동 폭
$3.02
$11.88
Cingulate Inc Stock (CING) Company Profile
명칭
Cingulate Inc
전화
(913) 942-2300
주소
1901 W. 47TH PLACE, KANSAS CITY
CING을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.19 | 21.41M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 개시 | ROTH MKM | Buy |
| 2023-12-22 | 다운그레이드 | Laidlaw | Buy → Hold |
Cingulate Inc 주식(CING)의 최신 뉴스
Cingulate price target lowered to $10 from $11 at Roth Capital - TipRanks
Cingulate places CEO Schaffer on administrative leave - MSN
Cingulate Inc. Reports Q2 2025 Financial Results - TipRanks
Cingulate reports Q2 net loss ($4.8M) vs ($3.2M) last year - MSN
Cingulate Inc. SEC 10-Q Report - TradingView
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights - The Manila Times
Cingulate Inc. Submits New Drug Application for Lead Asset CTx-1301, Anticipates FDA Decision in Q4 2025 - AInvest
Novel Once-Daily ADHD Drug Shows Full-Day Efficacy: Cingulate Submits FDA Application for CTx-1301 - Stock Titan
Cingulate Installs Interim Leadership After CEO Put On Administrative Leave - insights.citeline.com
Cingulate Inc CEO Shane Schaffer on Administrative Leave - MSN
What risks could impact Cingulate Inc. Equity Warrant stock performanceQuarterly Portfolio Report & Weekly High Conviction Trade Ideas - beatles.ru
Why Cingulate Inc. stock attracts strong analyst attentionPortfolio Risk Summary & Weekly Top Gainers Alerts - thegnnews.com
Quant Tools Rank Cingulate Inc. as High Risk High RewardJuly 2025 Review & Daily Volume Surge Trade Alerts - classian.co.kr
What’s the MACD signal for Cingulate Inc. Equity WarrantJuly 2025 Decliners & AI Powered Market Entry Ideas - thegnnews.com
Cingulate Inc. Delays Q2 Financial Report Filing Due to Management Changes. - AInvest
Cingulate Inc. Delays Quarterly Report Filing - MSN
Sector Leaders Rotate Capital Into Cingulate Inc.2025 Top Gainers & Real-Time Chart Breakout Alerts - 선데이타임즈
Cingulate Inc. Tests 50 Day MA After Sharp DeclineJuly 2025 Levels & Technical Buy Zone Confirmation - newsimpact.co.kr
KC company puts CEO on leave days after second domestic battery arrest - yahoo.com
Cingulate puts CEO on leave days after second domestic battery arrest - The Business Journals
Is This a Bottoming Phase for Cingulate Inc.Market Activity Summary & Community Consensus Trade Alerts - 선데이타임즈
Cingulate places CEO Shane Schaffer on leave, appoints interim leadership By Investing.com - Investing.com Nigeria
Cingulate Places CEO Shane Schaffer on Administrative Leave - MarketScreener
Cingulate places CEO on leave, appoints interim leadership By Investing.com - Investing.com Nigeria
Cingulate places CEO on leave, appoints interim leadership - Investing.com
Cingulate Inc. Appoints Jennifer Callahan, Chief Financial Officer to Serve as Interim Chief Executive Officer, Effective August 14, 2025 - MarketScreener
Cingulate Provides Management Team Update - GlobeNewswire
Leadership Change: Cingulate Appoints CFO Jennifer Callahan as Interim CEO Amid ADHD Drug FDA Review - Stock Titan
Analysts Spot Bullish Divergence in Cingulate Inc.Dividend Hike & Free Fast Entry Momentum Trade Alerts - newsyoung.net
KC-area public company CEO faces felony charge for choking his girlfriend - FOX4KC.com
Can Cingulate Inc. deliver consistent EPS growthFed Meeting & Stepwise Trade Execution Plans - classian.co.kr
Investors Hope for Bounce in Cingulate Inc. Equity Warrant After SelloffFree Access to Community - beatles.ru
Cingulate terminates COO one day after submitting drug for FDA approval - The Business Journals
Analyzing drawdowns of Cingulate Inc. with statistical toolsTrade Ideas Based on Fundamental Metrics - Newser
Why Cingulate Inc. Equity Warrant is moving todayFree Chart Driven High Reward Trading Setup - Newser
Identifying reversal signals in Cingulate Inc. Equity WarrantAI Powered Buy Point Forecast Planner - Newser
How to read the order book for Cingulate Inc.Free Trade Scanner With Buy Zone Alerts - Newser
Smart tools for monitoring Cingulate Inc.’s price actionFree Short Term Setup With Predictive Chart - Newser
Does Cingulate Inc. Equity Warrant show high probability of reboundFree Triple Return Setup with Risk Control - Newser
Is Cingulate Inc. Equity Warrant reversing from oversold territoryReal Time Stock Movement and Alerts - Newser
Understanding Cingulate Inc.’s price movementFree Pattern Alert With ROI Driven Strategy - Newser
What technical models suggest about Cingulate Inc.’s comebackTechnical Insight Guide for Safer Trades - Newser
Using R and stats models for Cingulate Inc. Equity Warrant forecastingSwing Reversal Forecast Based on Patterns - Newser
Using data filters to optimize entry into Cingulate Inc. Equity WarrantEntry Timing with Downside Risk Analysis - Newser
Cingulate CEO tells Roth COO departure has no meaningful impact on CTx-1301 - TipRanks
What momentum shifts mean for Cingulate Inc.Swing Trade Timing with Daily Forecast - Newser
Cingulate Inc.’s Strategic Partnerships and NDA Submission Drive Buy Rating - TipRanks
Cingulate submits CTx-1301 NDA to FDA - TipRanks
Cingulate Inc Submits NDA for ADHD Treatment - TipRanks
Cingulate submits NDA for ADHD treatment to FDA By Investing.com - Investing.com Canada
Cingulate submits NDA for ADHD treatment to FDA - Investing.com
Cingulate Inc (CING) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
1.72%
자본화:
|
볼륨(24시간):